Ex-Ru­bius CEO dusts him­self off at a dif­fer­ent Flag­ship biotech; Hutchmed switch­es things up dur­ing pipeline re­fo­cus

→ We led off Peer Re­view two weeks ago with what re­mains of Ru­bius Ther­a­peu­tics — and it’s not much. But ex-CEO Pablo Cagnoni has quick­ly re­bound­ed at an­oth­er Flag­ship biotech, tak­ing con­trol at a place where he’s been a board mem­ber for the last year. Cagnoni is suc­ceed­ing in­ter­im CEO John Mendlein at End­less RNA (eR­NA) biotech Laronde, which had the ex­cep­tion­al­ly lofty am­bi­tion of de­vel­op­ing 100 drugs by 2031 up­on its May 2021 launch and then raised $440 mil­lion in a Se­ries B to put the wheels in mo­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER